

Patient Information		Specimen Information	Client Information
DOB: Gender: Phone: Patient ID: Health ID:	AGE: Fasting:	Specimen: Requisition: Lab Ref #: Collected: Received: Reported:	REQUEST A TEST - PWN HEALTH 7027 MILL RD STE 201 BRECKSVILLE, OH 44141-1852

COMMENTS: FASTING:YES

LIPID PANEL, STANDARD  CHOLESTEROL, TOTAL 176	COMMENTS: FAST	<u> </u>		B. 6	
CHOLESTEROL, TOTAL 176	Test Name	In Ran	ge Out Of Ran	nge Reference Range	Lab
CHOLESTEROL, TOTAL 176	LIPID PANEL, STAN	DARD			
HDL CHOLESTEROL 61 TRIGLYCERIDES 48 LDL-CROLESTEROL 76 Reference range: <100  Desirable range <100 mg/dL for primary prevention; <70 mg/dL for patients with CHD or diabetic patients with > or = 2 CHD risk factors.  LDL-C is now calculated using the Martin-Hopkins calculation, which is a validated novel method providing better accuracy than the Friedewald equation in the estimation of LDL-C. Martin SS et al. JAMA. 2013;310(19): 2061-2068 (http://education.QuestDiagnostics.com/faq/FAQ164) CHOL/HDLC RATIO 2.9 < 5.0 (calc) FOR patients with diabetes plus 1 major ASCVD risk factor, treating to a non-HDL-C goal of <100 mg/dL (LDL-C of <70 mg/dL) is considered a therapeutic option.  HS CRP 0.3 mg/L  Reference Range Optimal <1.0 Jellinger PS et al. Endocr Pract.2017;23(Suppl 2):1-87.  For ages >17 Years: hs-CRP mg/L Risk According to AHA/CDC Guidelines <1.0 Lower relative cardiovascular risk.  1.0-3.0 Average relative cardiovascular risk.  3.1-10.0 Higher relative cardiovascular risk.				<200 mg/dl	AT
TRIGLYCERIDES 48 LDL-CHOLESTEROL 76 Reference range: <100  Desirable range <100 mg/dL for primary prevention; <70 mg/dL for patients with CHD or diabetic patients with > or = 2 CHD risk factors.  LDL-C is now calculated using the Martin-Hopkins calculation, which is a validated novel method providing better accuracy than the Friedewald equation in the estimation of LDL-C. Martin SS et al. JAMM. 2013;310(19): 2061-2068 (http://education.QuestDiagnostics.com/faq/FAQ164) CHOL/HDLC RATIO 2.9 <5.0 (calc) NON HDL CHOLESTEROL 115 <130 mg/dL (calc) For patients with diabetes plus 1 major ASCVD risk factor, treating to a non-HDL-C goal of <100 mg/dL (LDL-C of <70 mg/dL) is considered a therapeutic option.  HS CRP 0.3 mg/L  Reference Range Optimal <1.0 Jellinger PS et al. Endocr Pract.2017;23(Suppl 2):1-87.  For ages >17 Years: hs-CRP mg/L Risk According to AHA/CDC Guidelines <1.0 Lower relative cardiovascular risk.  1.0-3.0 Average relative cardiovascular risk.  3.1-10.0 Higher relative cardiovascular risk.					AT
LDL-CHOLESTEROL 76 mg/dL (calc)  Reference range: <100 mg/dL for primary prevention; <70 mg/dL for patients with CHD or diabetic patients with > or = 2 CHD risk factors.  LDL-C is now calculated using the Martin-Hopkins calculation, which is a validated novel method providing better accuracy than the Friedewald equation in the estimation of LDL-C.  Martin SS et al. JAMA. 2013;310(19): 2061-2068 (http://education.questDiagnostics.com/faq/FAQ164) CHOL/HDLC RATIO 2.9 <5.0 (calc) NON HDL CHOLESTEROL 115 <130 mg/dL (calc) For patients with diabetes plus 1 major ASCVD risk factor, treating to a non-HDL-C goal of <100 mg/dL (LDL-C of <70 mg/dL) is considered a therapeutic option.  HS CRP 0.3 mg/L  Reference Range Optimal <1.0 Jellinger PS et al. Endocr Pract.2017;23(Suppl 2):1-87.  For ages >17 Years: hs-CRP mg/L Risk According to AHA/CDC Guidelines <1.0 Lower relative cardiovascular risk.  1.0-3.0 Average relative cardiovascular risk.  3.1-10.0 Higher relative cardiovascular risk.					AT
Reference range: <100  Desirable range <100 mg/dL for primary prevention; <70 mg/dL for patients with CHD or diabetic patients with > or = 2 CHD risk factors.  LDL-C is now calculated using the Martin-Hopkins calculation, which is a validated novel method providing better accuracy than the Friedewald equation in the estimation of LDL-C. Martin SS et al. JAMA. 2013;310(19): 2061-2068 (http://education.QuestDiagnostics.com/faq/FAQ164) CHOL/HDLC RATIO 2.9 <5.0 (calc) CHOL/HDLC RATIO 1.5 <130 mg/dL (calc) For patients with diabetes plus 1 major ASCVD risk factor, treating to a non-HDL-C goal of <100 mg/dL (LDL-C of <70 mg/dL) is considered a therapeutic option.  HS CRP 0.3 mg/L  Reference Range Optimal <1.0 Jellinger PS et al. Endocr Pract.2017;23(Suppl 2):1-87.  For ages >17 Years: hs-CRP mg/L Risk According to AHA/CDC Guidelines <1.0 Lower relative cardiovascular risk.  1.0-3.0 Average relative cardiovascular risk.  3.1-10.0 Higher relative cardiovascular risk.					AT
<pre>&lt;70 mg/dL for patients with CHD or diabetic patients with &gt; or = 2 CHD risk factors.  LDL-C is now calculated using the Martin-Hopkins calculation, which is a validated novel method providing better accuracy than the Friedewald equation in the estimation of LDL-C. Martin SS et al. JAMA. 2013;310(19): 2061-2068 (http://education.QuestDiagnostics.com/faq/FAQ164) CHOL/HDLC RATIO 2.9 </pre> <pre> NON HDL CHOLESTEROL 115 &lt; 5.0 (calc) For patients with diabetes plus 1 major ASCVD risk factor, treating to a non-HDL-C goal of &lt;100 mg/dL (LDL-C of &lt;70 mg/dL) is considered a therapeutic option.  HS CRP 0.3 mg/L  Reference Range Optimal &lt;1.0 Jellinger PS et al. Endocr Pract.2017;23(Suppl 2):1-87.  For ages &gt;17 Years: hs-CRP mg/L Risk According to AHA/CDC Guidelines &lt;1.0 Lower relative cardiovascular risk.  1.0-3.0 Average relative cardiovascular risk. 3.1-10.0 Higher relative cardiovascular risk.</pre>		2 74 2 2 2 2 2 2 2			
calculation, which is a validated novel method providing better accuracy than the Friedewald equation in the estimation of LDL-C.  Martin SS et al. JAMA. 2013;310(19): 2061-2068 (http://education.QuestDiagnostics.com/faq/FAQ164)  CHOL/HDLC RATIO 2.9 <5.0 (calc) FOR PARTIC TOWN HDL CHOLESTEROL 115 (130 mg/dL (calc))  For patients with diabetes plus 1 major ASCVD risk factor, treating to a non-HDL-C goal of <100 mg/dL (LDL-C of <70 mg/dL) is considered a therapeutic option.  HS CRP 0.3 mg/L  Reference Range Optimal <1.0  Jellinger PS et al. Endocr Pract.2017;23(Suppl 2):1-87.  For ages >17 Years: hs-CRP mg/L Risk According to AHA/CDC Guidelines <1.0 Lower relative cardiovascular risk.  1.0-3.0 Average relative cardiovascular risk.  1.0-3.0 Higher relative cardiovascular risk.	<70 mg/dL fo	or patients with CHD or o		S	
calculation, which is a validated novel method providing better accuracy than the Friedewald equation in the estimation of LDL-C.  Martin SS et al. JAMA. 2013;310(19): 2061-2068 (http://education.QuestDiagnostics.com/faq/FAQ164)  CHOL/HDLC RATIO 2.9 <5.0 (calc) FOR PARTIC TOWN HDL CHOLESTEROL 115 (130 mg/dL (calc))  For patients with diabetes plus 1 major ASCVD risk factor, treating to a non-HDL-C goal of <100 mg/dL (LDL-C of <70 mg/dL) is considered a therapeutic option.  HS CRP 0.3 mg/L  Reference Range Optimal <1.0  Jellinger PS et al. Endocr Pract.2017;23(Suppl 2):1-87.  For ages >17 Years: hs-CRP mg/L Risk According to AHA/CDC Guidelines <1.0 Lower relative cardiovascular risk.  1.0-3.0 Average relative cardiovascular risk.  3.1-10.0 Higher relative cardiovascular risk.	LDL-C is no	v calculated using the Ma	artin-Hopkins		
better accuracy than the Friedewald equation in the estimation of LDL-C.  Martin SS et al. JAMA. 2013;310(19): 2061-2068 (http://education.QuestDiagnostics.com/faq/FAQ164)  CHOL/HDLC RATIO 2.9 <5.0 (calc)  NON HDL CHOLESTEROL 115 <130 mg/dL (calc)  For patients with diabetes plus 1 major ASCVD risk factor, treating to a non-HDL-C goal of <100 mg/dL (LDL-C of <70 mg/dL) is considered a therapeutic option.  HS CRP 0.3 mg/L  Reference Range Optimal <1.0  Jellinger PS et al. Endocr Pract.2017;23(Suppl 2):1-87.  For ages >17 Years: hs-CRP mg/L Risk According to AHA/CDC Guidelines <1.0 Lower relative cardiovascular risk.  1.0-3.0 Average relative cardiovascular risk. 3.1-10.0 Higher relative cardiovascular risk.				iding	
estimation of LDL-C. Martin SS et al. JAMA. 2013;310(19): 2061-2068 (http://education.QuestDiagnostics.com/faq/FAQ164)  CHOL/HDLC RATIO 2.9 <5.0 (calc) FOR PATION TO THE PROOF OF THE PROO					
(http://education.QuestDiagnostics.com/faq/FAQ164) CHOL/HDLC RATIO 2.9			*		
CHOL/HDLC RATIO  NON HDL CHOLESTEROL  For patients with diabetes plus 1 major ASCVD risk factor, treating to a non-HDL-C goal of <100 mg/dL (LDL-C of <70 mg/dL) is considered a therapeutic option.  HS CRP  Reference Range Optimal <1.0  Jellinger PS et al. Endocr Pract.2017;23(Suppl 2):1-87.  For ages >17 Years: hs-CRP mg/L Risk According to AHA/CDC Guidelines <1.0  Lower relative cardiovascular risk.  1.0-3.0  Average relative cardiovascular risk.  3.1-10.0  Higher relative cardiovascular risk.	Martin SS e	al. JAMA. 2013;310(19):	: 2061-2068		
NON HDL CHOLESTEROL  For patients with diabetes plus 1 major ASCVD risk factor, treating to a non-HDL-C goal of <100 mg/dL (LDL-C of <70 mg/dL) is considered a therapeutic option.  HS CRP  Reference Range Optimal <1.0 Jellinger PS et al. Endocr Pract.2017;23(Suppl 2):1-87.  For ages >17 Years: hs-CRP mg/L Risk According to AHA/CDC Guidelines <1.0 Lower relative cardiovascular risk.  1.0-3.0 Average relative cardiovascular risk. 3.1-10.0 Higher relative cardiovascular risk.	(http://edu	cation.QuestDiagnostics.c	com/faq/FAQ164)		
For patients with diabetes plus 1 major ASCVD risk factor, treating to a non-HDL-C goal of <100 mg/dL (LDL-C of <70 mg/dL) is considered a therapeutic option.  HS CRP 0.3 mg/L Patient of the patient of	CHOL/HDLC RATIO	2.9		<5.0 (calc)	AT
factor, treating to a non-HDL-C goal of <100 mg/dL (LDL-C of <70 mg/dL) is considered a therapeutic option.  HS CRP 0.3 mg/L  Reference Range Optimal <1.0 Jellinger PS et al. Endocr Pract.2017;23(Suppl 2):1-87.  For ages >17 Years: hs-CRP mg/L Risk According to AHA/CDC Guidelines <1.0 Lower relative cardiovascular risk.  1.0-3.0 Average relative cardiovascular risk. 3.1-10.0 Higher relative cardiovascular risk.				<130 mg/dL (calc)	AT
(LDL-C of <70 mg/dL) is considered a therapeutic option.  HS CRP 0.3 mg/L Part of the control of					
option.  HS CRP 0.3 mg/L  Reference Range Optimal <1.0 Jellinger PS et al. Endocr Pract.2017;23(Suppl 2):1-87.  For ages >17 Years: hs-CRP mg/L hs-CRP mg/L Lower relative cardiovascular risk.  1.0-3.0 Average relative cardiovascular risk. 3.1-10.0 Higher relative cardiovascular risk.					
HS CRP 0.3 mg/L  Reference Range Optimal <1.0 Jellinger PS et al. Endocr Pract.2017;23(Suppl 2):1-87.  For ages >17 Years: hs-CRP mg/L No-CRP mg/L No-		$^{\prime}$ 0 mg/dL) is considered a	a therapeutic		
Reference Range Optimal <1.0 Jellinger PS et al. Endocr Pract.2017;23(Suppl 2):1-87.  For ages >17 Years: hs-CRP mg/L Risk According to AHA/CDC Guidelines <1.0 Lower relative cardiovascular risk.  1.0-3.0 Average relative cardiovascular risk. 3.1-10.0 Higher relative cardiovascular risk.	CONTRACTOR OF THE CONTRACTOR O			Newson and April	
Optimal <1.0 Jellinger PS et al. Endocr Pract.2017;23(Suppl 2):1-87.  For ages >17 Years: hs-CRP mg/L Risk According to AHA/CDC Guidelines <1.0 Lower relative cardiovascular risk.  1.0-3.0 Average relative cardiovascular risk. 3.1-10.0 Higher relative cardiovascular risk.				mg/L	AT
Jellinger PS et al. Endocr Pract.2017;23(Suppl 2):1-87.  For ages >17 Years: hs-CRP mg/L Risk According to AHA/CDC Guidelines <1.0 Lower relative cardiovascular risk.  1.0-3.0 Average relative cardiovascular risk. 3.1-10.0 Higher relative cardiovascular risk.					
For ages >17 Years: hs-CRP mg/L Risk According to AHA/CDC Guidelines <1.0 Lower relative cardiovascular risk.  1.0-3.0 Average relative cardiovascular risk.  3.1-10.0 Higher relative cardiovascular risk.					
hs-CRP mg/L Risk According to AHA/CDC Guidelines <1.0 Lower relative cardiovascular risk.  1.0-3.0 Average relative cardiovascular risk.  3.1-10.0 Higher relative cardiovascular risk.	Jellinger P	et al. Endocr Pract.201	17;23(Suppl 2):1-	-87.	
<1.0 Lower relative cardiovascular risk. 1.0-3.0 Average relative cardiovascular risk. 3.1-10.0 Higher relative cardiovascular risk.	For ages >1	Years:			
<1.0 Lower relative cardiovascular risk. 1.0-3.0 Average relative cardiovascular risk. 3.1-10.0 Higher relative cardiovascular risk.	hs-CRP mg/L	Risk According to AHA/(	CDC Guidelines		
3.1-10.0 Higher relative cardiovascular risk.					
3.1-10.0 Higher relative cardiovascular risk.	1 0-3 0	Average relative cardi	ovacoular rick	2	
Consider retesting in 1 to 2 weeks to	3.1 10.0				
exclude a benign transient elevation					
in the baseline CRP value secondary					
to infection or inflammation.					
>10.0 Persistent elevation, upon retesting,	>10.0				
may be associated with infection and	710.0				
inflammation.			. Intereston and		

Report Status: Final



Patient Information		Specimen Information	Client Information
DOB: Gender: Patient ID: Health ID:	AGE: Fasting:	Specimen: Collected: Received: Reported:	

Test Name In Range Out Of Range Reference Range Lab
LIPOPROTEIN (a) <10 <75 nmol/L AMD

Assay was repeated and verified.

Risk Category
Optimal < 75 nmol/L
Moderate 75 - 125 nmol/L
High > 125 nmol/L

Cardiovascular event risk category cut points (optimal, moderate, high) are based on Tsimika S. JACC 2017;69:692-711.